IPG PHOTONICS CORP (IPGP)
Sector: Information Technology
2026 Annual Meeting Analysis
IPG PHOTONICS CORP · Meeting: May 12, 2026
Directors FOR
3
Directors AGAINST
7
Say on Pay
FOR
Auditor
AGAINST
Director Elections
Election of Ten Directors
Against Analysis
Ms. Desmond has served since 2021, giving her full overlap with the three-year period during which IPGP's stock fell roughly 6% while the company's own disclosed peer group rose a median of 80.5% — a gap of about 86 percentage points, far exceeding the 20-point trigger threshold for companies with negative absolute returns; the five-year record is even worse, so the mitigant that would allow a downgrade to FOR does not apply.
Mr. Dougherty has served since 2019, giving him full overlap with both the three- and five-year underperformance periods; IPGP's stock lost roughly 6% over three years while the peer group median gained 80.5%, a gap of 86 percentage points that far exceeds the policy trigger, and the five-year record confirms sustained underperformance rather than a transient trough.
Mr. Meurice has served since 2014 and carries the longest tenure overlap with the sustained underperformance period; IPGP shareholders lost roughly 49% over five years while the peer group gained a median of 57.5%, a gap of over 106 percentage points, confirming that the three-year trigger reflects long-running destruction of shareholder value rather than a temporary dip.
Ms. Pavlova has served since 2021 and is the spouse of a senior executive officer of the company, which is a direct familial relationship to senior management that raises governance concerns regardless of her status as a significant stockholder; additionally, the same severe TSR underperformance trigger that applies to other directors with similar tenure applies here, and the five-year record does not provide the mitigant needed to downgrade the vote to FOR.
Mr. Peeler has served since 2012 and has been non-executive Chair since 2021, making him the director most directly accountable for board oversight during the entire underperformance period; shareholders lost roughly 49% over five years against a peer group that gained over 57%, and the five-year TSR gap of more than 106 percentage points confirms sustained rather than transient underperformance.
Dr. Scherbakov has served on the board since 2000 and served as CEO until June 2024, giving him the longest overlap with the company's strategic decisions that led to severe underperformance relative to peers; the five-year record shows no recovery signal that would justify downgrading the vote to FOR.
Ms. Tang joined in March 2022, which is more than 24 months before the meeting, so the new-director exemption does not apply; while her tenure is shorter than most other directors, her overlap with the underperformance period is sufficient for the trigger to apply, and the five-year record does not provide the mitigant needed to downgrade the vote to FOR.
For Analysis
Joined in January 2023, which is within 24 months of the meeting date, so he is exempt from the TSR underperformance trigger; strong financial and audit credentials make him a well-qualified director.
Dr. Gitin joined the board in June 2024, which is within 24 months of the meeting date, making him exempt from the TSR underperformance trigger; as the newly recruited CEO leading a stated turnaround, he has not had a meaningful opportunity to influence the prior underperformance period.
Ms. Kennedy joined in August 2023, which is within 24 months of the meeting date, so she is exempt from the TSR underperformance trigger; her medical device and healthcare leadership background adds relevant skills as IPG expands its medical product line.
Six of ten director nominees receive an AGAINST vote due to the company's severe and sustained TSR underperformance relative to its own disclosed peer group — IPGP's stock fell roughly 6% over three years while the peer median rose about 80%, a gap of 86 percentage points that far exceeds the 20-point policy trigger for companies with negative absolute returns; the five-year gap of over 106 percentage points confirms this is not a transient trough. The four nominees receiving FOR votes are either within the 24-month new-director exemption window (Beecher, Gitin, Kennedy) or are too new to carry meaningful accountability (Gitin). Natalia Pavlova additionally triggers the familial-relationship flag as spouse of a senior executive officer.
Say on Pay
✓ FORCEO
Mark Gitin
Total Comp
$9,071,490
Prior Support
96%%
The prior say-on-pay vote received over 96% support, well above the 70% threshold that would require a response check, and the compensation structure is strongly performance-oriented — approximately 90% of the CEO's target pay is variable or at-risk, performance stock awards paid out at zero for PSUs vesting in 2025 (reflecting real business underperformance), and the annual incentive paid out at roughly 114% of target reflecting genuine revenue and profit improvement against pre-set goals. The CEO's total reported compensation of approximately $9.1 million reflects a one-time enhanced equity award that the board disclosed was intended to retain a newly recruited leader and bring his unvested equity holdings closer to the peer median, which is a plausible rationale rather than an unexplained windfall. The program includes a meaningful clawback policy, stock ownership requirements, caps on incentive payouts, and no guaranteed bonuses, meeting the structural quality standards of the policy.
Auditor Ratification
✗ AGAINSTAuditor
Deloitte & Touche LLP
Tenure
27 yrs
Audit Fees
$2,476,200
Non-Audit Fees
$3,157
Deloitte & Touche has audited IPG since 1999, a relationship of approximately 27 years that exceeds the policy's 25-year tenure threshold; while the proxy notes that a new lead audit partner was approved for the 2024 audit and the next required rotation is 2029, partner rotation alone does not constitute the specific and compelling rationale required by policy to override the tenure trigger, and non-audit fees are a negligible $3,157 so the fee ratio is not an issue.
Overall Assessment
The 2026 IPG Photonics annual meeting presents a mixed ballot: Say on Pay earns a FOR given strong structural alignment and 96% prior-year support, but Auditor Ratification draws an AGAINST due to a 27-year tenure that exceeds the policy threshold without a sufficiently compelling rationale for continuation. Six of ten director nominees receive AGAINST votes reflecting severe and sustained stock underperformance relative to the company's own peer group — a gap of over 86 percentage points over three years and over 106 percentage points over five years — with FOR votes reserved only for directors joining within the past 24 months.
Compensation Peer Group
19 companies disclosed in 2026 proxy filing